NasdaqCM - Delayed Quote USD

Bone Biologics Corporation (BBLGW)

Compare
11.00 +9.34 (+562.65%)
At close: October 18 at 4:00 PM EDT
Loading Chart for BBLGW
DELL
  • Previous Close 1.66
  • Open 3.00
  • Bid --
  • Ask --
  • Day's Range 3.00 - 11.00
  • 52 Week Range 0.70 - 70.44
  • Volume 3,009
  • Avg. Volume 53
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) --
  • EPS (TTM) -0.14
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

www.bonebiologics.com

2

Full Time Employees

--

Fiscal Year Ends

Recent News: BBLGW

View More

Performance Overview: BBLGW

Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BBLGW
180.61%
S&P 500
22.95%

1-Year Return

BBLGW
166.34%
S&P 500
34.10%

3-Year Return

BBLGW
909.17%
S&P 500
31.16%

5-Year Return

BBLGW
1,191.08%
S&P 500
34.39%

Compare To: BBLGW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BBLGW

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -57.25%

  • Return on Equity (ttm)

    -119.03%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -5.12M

  • Diluted EPS (ttm)

    -0.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.33M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -4.83M

Research Analysis: BBLGW

View More

Company Insights: BBLGW

Research Reports: BBLGW

View More

People Also Watch